142 related articles for article (PubMed ID: 10925359)
1. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma.
Letsch A; Keilholz U; Schadendorf D; Nagorsen D; Schmittel A; Thiel E; Scheibenbogen C
Int J Cancer; 2000 Sep; 87(5):659-64. PubMed ID: 10925359
[TBL] [Abstract][Full Text] [Related]
2. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.
Scheibenbogen C; Sun Y; Keilholz U; Song M; Stevanovic S; Asemissen AM; Nagorsen D; Thiel E; Rammensee HG; Schadendorf D
Int J Cancer; 2002 Mar; 98(3):409-14. PubMed ID: 11920592
[TBL] [Abstract][Full Text] [Related]
3. Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.
Valmori D; Scheibenbogen C; Dutoit V; Nagorsen D; Asemissen AM; Rubio-Godoy V; Rimoldi D; Guillaume P; Romero P; Schadendorf D; Lipp M; Dietrich PY; Thiel E; Cerottini JC; Liénard D; Keilholz U
Cancer Res; 2002 Mar; 62(6):1743-50. PubMed ID: 11912149
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
5. A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients.
Scheibenbogen C; Lee KH; Mayer S; Stevanovic S; Moebius U; Herr W; Rammensee HG; Keilholz U
Clin Cancer Res; 1997 Feb; 3(2):221-6. PubMed ID: 9815676
[TBL] [Abstract][Full Text] [Related]
6. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
[TBL] [Abstract][Full Text] [Related]
7. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.
Scheibenbogen C; Lee KH; Stevanovic S; Witzens M; Willhauck M; Waldmann V; Naeher H; Rammensee HG; Keilholz U
Int J Cancer; 1997 Jun; 71(6):932-6. PubMed ID: 9185691
[TBL] [Abstract][Full Text] [Related]
9. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
10. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
11. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
12. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
13. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
Jenne L; Arrighi JF; Jonuleit H; Saurat JH; Hauser C
Cancer Res; 2000 Aug; 60(16):4446-52. PubMed ID: 10969791
[TBL] [Abstract][Full Text] [Related]
15. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C
Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594
[TBL] [Abstract][Full Text] [Related]
17. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
19. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
20. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types.
Harada M; Li YF; El-Gamil M; Ohnmacht GA; Rosenberg SA; Robbins PF
J Immunother; 2001; 24(4):323-33. PubMed ID: 11565834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
